Rotavirus Infections: all 104 studies
Page 1 of 2. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health PerspectiveRecruitingNCT07358910
- Phase II Clinical Trial of the Inactivated Rotavirus VaccineRecruitingNCT06080906Phase 2
- A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and IndiaRecruitingNCT04010448Phase 3
- Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 WeeksCompletedNCT03954743Phase 3Results posted
- A Phase II Dose-ranging Study of Oral RV3-BB Rotavirus VaccineCompletedNCT03483116Phase 2Results posted
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized VaccineCompletedNCT03207750Phase 3Results posted
- The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and ImmunogenicityCompletedNCT02992197Phase 4Results posted
- Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 WeeksCompletedNCT02914184Phase 3Results posted
- Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot StudyCompletedNCT02542462Phase 4Results posted
- Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)CompletedNCT01926015Phase 4Results posted
- A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus VaccineCompletedNCT01764256Phase 1Results posted
- Vaccine Effectiveness of RV1 in a Naïve PopulationCompletedNCT01467037Results posted
- Safety and Immunogenicity of Sequential Rotavirus Vaccine SchedulesCompletedNCT01266850Phase 4Results posted
- Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.CompletedNCT01198769Phase 4Results posted
- Gastroenteritis From Rotavirus Infection in Brazilian Children Less Than 5 Years of Age (Study V260-031).TerminatedNCT01195844Results posted
- Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese InfantsCompletedNCT01171963Phase 3Results posted
- Rotavirus Vaccine Produced by Butantan InstituteCompletedNCT00981669Phase 1Results posted
- Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean InfantsCompletedNCT00969228Phase 4Results posted
- Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian InfantsCompletedNCT00938327Results posted
- Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected MothersCompletedNCT00880698Phase 2Results posted
- Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United StatesCompletedNCT00875641Results posted
- Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in InfantsCompletedNCT00779779Results posted
- Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in InfantsCompletedNCT00750893Results posted
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of AgeCompletedNCT00533507Phase 3Results posted
- Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese InfantsCompletedNCT00480324Phase 3Results posted
- RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)CompletedNCT00443846Phase 3Results posted
- A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.CompletedNCT00432380Phase 2Results posted
- To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term InfantsCompletedNCT00420745Phase 3Results posted
- Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.CompletedNCT00420316Phase 3Results posted
- A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.CompletedNCT00396630Phase 3Results posted
- To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)CompletedNCT00363545Phase 3Results posted
- To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First VaccinationCompletedNCT00353366Results posted
- Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)CompletedNCT00329745Phase 3Results posted
- A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South AfricaCompletedNCT00263666Phase 2Results posted
- V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)CompletedNCT00258154Phase 3Results posted
- Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African InfantsCompletedNCT00241644Phase 3Results posted
- Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)CompletedNCT00130832Phase 3Results posted
- Consistency Lots Vaccine Study (V260-009)CompletedNCT00092456Phase 3Results posted
- Dose Confirmation Efficacy Study (V260-007)CompletedNCT00092443Phase 3Results posted
- Rotavirus Efficacy and Safety Trial (REST)(V260-006)CompletedNCT00090233Phase 3Results posted
- CDC-9 Inactivated Rotavirus Vaccine (IRV) Microneedle Patch (MNP) in Healthy AdultsActive, not recruitingNCT06962904Phase 1
- CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy AdultsCompletedNCT06485258Phase 1
- The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean InfantsActive, not recruitingNCT06200844Phase 3
- Safety and Immunogenicity Study of Recombinant Trivalent Rotavirus Subunit Vaccine in Healthy Infants and ToddlersActive, not recruitingNCT05621655Phase 2
- A Surveillance Study on Timing and Coverage Of Rotavirus and MenB Vaccine Co-administration in Campania Region, ItalyStatus unknownNCT05212935
- Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.CompletedNCT05037435Phase 3
- Reactogenicity, Safety and Immunological Efficacy of the Live, Pentavalent Rotavirus Vaccine in Childhood ImmunizationCompletedNCT05032391Phase 3
- Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus InfectionStatus unknownNCT04626856Phase 1
- Evaluation of an Infant Immunization Encouragement Program in NigeriaCompletedNCT03870061Not applicable
- Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in VietnamStatus unknownNCT03367559Phase 3
- SaniVac Trial - Sanitation and Oral Rotavirus Vaccine PerformanceCompletedNCT03313128
- The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children After Introduction of Rotavirus VaccinesStatus unknownNCT02662543
- The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune ResponsesCompletedNCT02538211Not applicable
- Does the Fecal Microbiome Influence Rotarix ImmunogenicityCompletedNCT02220439
- Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™CompletedNCT02153333
- Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe GastroenteritisWithdrawnNCT01978223
- Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix VaccinationCompletedNCT01915888
- Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus GastroenteritisCompletedNCT01733862
- A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5 Years of Age, in Bulgaria and LatviaCompletedNCT01733849
- Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) VaccinationCompletedNCT01682005
- Special Drug Use Investigation for ROTARIX®CompletedNCT01636739
- Drug Use Investigation for ROTARIX®CompletedNCT01636193
- Impact on Quality of Hospital Care During Pre- and Post- Rotavirus (RV) Vaccination Introduction in BelgiumCompletedNCT01592838
- Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2010-2011CompletedNCT01563159
- Number of Rotavirus (RV) Related Hospitalizations in Belgium - Season 2006-2007CompletedNCT01563146
- Serological Response to Porcine Circovirus Type 1 (PCV-1) and PCV-1 DNA in Stools of Infants Following Administration of Rotarix™CompletedNCT01511133
- Observational Study on Rotavirus Gastroenteritis Epidemiology, Impact of Lyophilised vs. Liquid Formulation of Rotarix™CompletedNCT01435967
- Surveillance of Rotavirus Gastroenteritis in Children <5 YearsStatus unknownNCT01363726
- ROTATEQ™ Post-Marketing Surveillance in the PhilippinesTerminatedNCT01357174
- Epidemiological, Observational and Post Marketing Study of Rotarix™ in Children With Severe Gastroenteritis in BelgiumCompletedNCT01339221
- Efficacy Study of Nitazoxanide Suspension in the Treatment of Rotavirus Disease in ChildrenCompletedNCT01328925Phase 2
- Surveillance Study to Estimate the Proportion of Rotavirus Gastroenteritis in Children < 5 Years of Age in RomaniaCompletedNCT01253967
- Effectiveness Study of GSK Biologicals' Rotarix TM Vaccine in Hospitalized ChildrenCompletedNCT01177826
- Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese AdultsCompletedNCT01162590Phase 1
- Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 VaccineWithdrawnNCT01110044Phase 2
- Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy InfantsCompletedNCT01107587Phase 1
- Study to Evaluate the Safety of Rotarix™ in Chinese ChildrenCompletedNCT01086436Phase 1
- Probiotics in the Management of Acute Rotavirus Diarrhea in Bolivian ChildrenCompletedNCT00981877Not applicable
- Two-year Surveillance of Rotavirus Genotypes Causing Acute Diarrhea in Children Younger Than 5 Years Requiring Emergency Room (ER) and Hospital Admission in ChileCompletedNCT00895492
- Safety and Immunogenicity Study of the Recombinant Human Bovine Reassortant Rotavirus Vaccine in Healthy Indian InfantsWithdrawnNCT00757926Phase 1/2
- Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV VaccineCompletedNCT00757770Phase 3
- Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.CompletedNCT00729001Phase 2
- Use of Nitazoxanide and Probiotics in Acute Diarrhea Secondary to RotavirusCompletedNCT00683982Not applicable
- Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in PanamaCompletedNCT00653198
- Hospital-based Surveillance to Collect Prospective Data to Estimate the Disease Burden of Severe RV GE in SwedenCompletedNCT00489567
- Surveillance of Hospitalizations Due to Rotavirus Infections Among Children From IsraelStatus unknownNCT00484952
- Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy InfantsCompletedNCT00425737Phase 2
- Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 MonthsCompletedNCT00385320Phase 2
- Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South AfricaCompletedNCT00383903Phase 2
- A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).CompletedNCT00382772Phase 3
- Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant VaccinesCompletedNCT00370318Phase 3
- To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPVCompletedNCT00346892Phase 2
- To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)CompletedNCT00345956Phase 3
- Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USACompletedNCT00334607Phase 3
- Study of Nitazoxanide Suspension in the Treatment of Diarrhea Caused by Enteric Viruses in ChildrenCompletedNCT00302640Phase 2/3
- Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in IndiaCompletedNCT00289172Phase 3
- Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in InfantsCompletedNCT00280111Phase 1
- A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy InfantsCompletedNCT00197210Phase 3
- To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood VaccinesCompletedNCT00140686Phase 3
- A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.CompletedNCT00140673Phase 3